On May 06, 2014, Novavax, Inc. (Nasdaq:NVAX), announced the appointment of Sven Andréasson to the position of Senior Vice President, Corporate Development, effective June 2, 2014. Novavax, Inc. (NASDAQ:NVAX), weekly performance is -1.84%. On last trading day company shares ended up $4.27. Analysts mean target price for the company is $11.20. Novavax, Inc. (NASDAQ:NVAX), distance from 50-day simple moving average (SMA50) is -8.39%.
XOMA Corp (NASDAQ:XOMA), shares moved higher after the company reported wider-than-expected loss per share in the Q1 of 2014 and slower-than-expected patient enrolment in two phase III studies being conducted with gevokizumab. XOMA Corp (NASDAQ:XOMA), advanced 7.97% in last trading session and ended the day on $3.93. XOMA, return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA), quarterly performance is -48.83%.
Array Biopharma Inc (NASDAQ:ARRY), announced its financial results for 3Q14. Revenue for the company was $7.8 million in 3Q14 as compared to $10 million for 3Q13. Revenue declined due to ending of Celgene Collaboration in 2013 which resulted in reduced license recognition and milestone payments. Net loss for 3Q14 was $24.9 million as compared to net loss of $21.6 million in 3Q13. There was a total of $110 million of cash equivalents, cash and marketable securities at the end of the quarter. Revenue for the nine months, ended 3Q14 was $36.1 million as compared to $44.2 million year-over-year. Net loss for nine months was $57 million as compared to $44.3 million year-over-year. Array Biopharma Inc (NASDAQ:ARRY), shares moved up 6.60% in last trading session and was closed at $4.20, while trading in range of $ 3.93 – 4.27. Array Biopharma Inc (NASDAQ:ARRY), year to date (YTD) performance is -16.17%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), announced financial and operational results for the first quarter ended March 31, 2014. Total revenues for the first quarter of 2014 were $9.1 million, compared to $8.1 million for the first quarter of 2013. First quarter 2014 revenues included $1.7 million in Fanapt royalties received from Novartis as compared to royalties of $1.5 million for the first quarter of 2013. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), ended the last trading day at $10.98. Company weekly volatility is calculated as 12.59% and price to cash ratio as 2.85. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), showed a negative weekly performance of 21.79%.
Leave a Reply